German pharmaceutical company Grünenthal has acquired the commercial rights to Eli Lilly's Cialis in Mexico, Brazil and Columbia.
Cialis, otherwise known as tadalafil, is suitable for the oral treatment of erectile dysfunction, as well as symptoms of benign prostatic hyperplasia in adult men.
This acquisition will boost Grünenthal's Latin American footprint, and follows the company's acquisition of Nebido, a long-lasting treatment for those with testosterone deficiency.
Under the terms of the agreement, Grünenthal and Eli Lilly will collaborate to transfer the manufacturing of Cialis to the former's production site in Santiago, Chile.
It's expected that the transaction — the financial terms of which were not disclosed — will close in the third quarter of this year, subject to the satisfaction of customary closing conditions.
"Executing on our strategy of targeted acquisitions, Cialis® will expand our existing portfolio in the region and strengthen Grünenthal's Latin American business", said Grünenthal's CEO, Gabriel Baertschi.
"In 2022, we acquired Nebido, a long-acting treatment for testosterone deficiency, and with Cialis we can continue to serve our existing customer base and foster our growth in key Latin American markets."
The acquisition of Cialis falls in line with Grünenthal's continued strategy to acquire established medicines, allowing the company to expand its portfolio and increase its profitability.
Since 2017, Grünenthal has invested more than €2bn into acquisitions; giving it the rights to Nebido, Nexium, Vimovo, Qutenza and Zomig in selected geographies.
In 2023, Grünenthal established Grünenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management and, in 2024, acquired the US company Valinor Pharma and the product Movantik.